CA Patent

CA2547820A1 — (s)-2-n-propylamino-5-hydroxytetralin as a d3 agonist

Assigned to UCB Pharma GmbH · Expires 2005-06-30 · 21y expired

What this patent protects

The invention relates to a medicament containing (S)-2-N-propylamino-5-hydroxytetralin, the salts or prodrugs thereof. As a D3 agonist, (S)-2-N-propylamino-5-hydroxytetralin is suitable particularly for the treatment of dopa-sensitive movement disorders.

USPTO Abstract

The invention relates to a medicament containing (S)-2-N-propylamino-5-hydroxytetralin, the salts or prodrugs thereof. As a D3 agonist, (S)-2-N-propylamino-5-hydroxytetralin is suitable particularly for the treatment of dopa-sensitive movement disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA2547820A1
Jurisdiction
CA
Classification
—
Expires
2005-06-30
Drug substance claim
No
Drug product claim
No
Assignee
UCB Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.